p53 and retinoid chemoprevention of oral carcinogenesis.
We studied p53 protein's pattern of expression, association with retinoid response or resistance, and modulation by retinoid intervention in oral premalignancy. These p53 analyses were included in a prospective trial of the retinoid isotretinoin (1.5 mg/kg/day for 3 months) in 40 patients (45 oral premalignant lesions). Seven nonsmoking subjects (eight oral biopsies) were included as a control. Protein levels of p53 were determined separately for the whole epithelium and the basal, parabasal, and superficial layers. A wide range of accumulated p53 protein levels occurred in 40 (89%) of 45 lesions in basal and parabasal but not superficial layers. No p53 protein was detected in any normal controls. Accumulation of p53 increased in direct association with histological grade (P = 0.0004). An inverse relationship occurred between the levels of accumulated p53 protein and response to isotretinoin (P = 0.006). High-dose isotretinoin did not modulate accumulated p53 protein expression.
Lippman
S M
SM
Department of Thoracic/Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Shin
D M
DM
Lee
J J
JJ
Batsakis
J G
JG
Lotan
R
R
Tainsky
M A
MA
Hittelman
W N
WN
Hong
W K
WK
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000008:administration & dosage / Q000627:therapeutic use*; D007971:Leukoplakia / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011230:Precancerous Conditions / Q000188:drug therapy* / Q000378:metabolism; D011446:Prospective Studies; D013997:Time Factors; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
D016159:Tumor Suppressor Protein p53; D015474:Isotretinoin